StockData
Bioventus Inc. logo

Bioventus Inc. (BVS) stock

BVSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Nov 2, 2026Score 13/3041% below fair value
$10.60+0.14 (+1.34%)

Close on Nov 17, 2026Market cap $891.37MP/E 13.8Yield –

Bioventus operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Bioventus's operating income for the twelve months ending Jun 27, 2026 was $58.28M, up 68.5% year over year. For fiscal 2025 it was $53.98M. The highest annual figure on record is $53.98M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$53.98M–
FY2024Dec 31, 2024-$15.20M–
FY2023Dec 31, 2023-$81.73M–
FY2022Dec 31, 2022-$167.23M-1486.6%
FY2021Dec 31, 2021$12.06M-43.2%
FY2020Dec 31, 2020$21.24M-31.9%
FY2019Dec 31, 2019$31.19M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 27, 2026$19.13M+4.1%
Q1 FY2026Mar 28, 2026$8.42M+72.8%
Q4 FY2025Dec 31, 2025$19.49M+153.0%
Q3 FY2025Sep 27, 2025$11.25M+208.5%
Q2 FY2025Jun 28, 2025$18.37M–
Q1 FY2025Mar 29, 2025$4.87M-1.2%
Q4 FY2024Dec 31, 2024$7.70M+561.2%
Q3 FY2024Sep 28, 2024$3.65M+50.8%
Q2 FY2024Jun 29, 2024-$31.47M-566.3%
Q1 FY2024Mar 30, 2024$4.93M–
Q4 FY2023Dec 31, 2023$1.17M–
Q3 FY2023Sep 30, 2023$2.42M–
Q2 FY2023Jul 1, 2023$6.75M–
Q1 FY2023Apr 1, 2023-$92.06M–
Q4 FY2022Dec 31, 2022-$15.64M–
Q3 FY2022Oct 1, 2022-$126.84M–
Q2 FY2022Jul 2, 2022-$3.31M–
Q1 FY2022Apr 2, 2022-$21.45M-197.5%
Q4 FY2021Dec 31, 2021-$3.15M-153.3%
Q3 FY2021Oct 2, 2021-$1.05M-115.1%
Q2 FY2021Jul 3, 2021-$5.74M–
Q1 FY2021Apr 3, 2021$22.00M+69.4%
Q4 FY2020Dec 31, 2020$5.91M–
Q3 FY2020Sep 26, 2020$6.93M–
Q2 FY2020Jun 27, 2020-$4.59M–
Q1 FY2020Mar 28, 2020$12.99M–

More Bioventus figures

See a number that looks wrong?